| |
| |
|
| Insider
Information: |
Kauffman Michael |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
800,347 |
|
|
Indirect Shares
|
898,131 |
|
|
| Direct
Value |
$881,257 |
|
|
|
Indirect Value
|
$916,094 |
|
|
| Total
Shares |
1,698,478 |
|
|
| Total
Value |
$1,797,350 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
12
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
12
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-12.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -553.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
Chief Medical Officer |
2010-02-09 |
9,000 |
2009-11-16 |
0 |
Premium* |
|
|
Karyopharm Therapeutics Inc. |
KPTI |
Director |
2022-02-28 |
713,757 |
2022-02-28 |
898,131 |
Premium* |
|
|
Verastem, Inc. |
VSTM |
Director |
2018-09-28 |
8,000 |
2014-09-17 |
0 |
Premium* |
|
|
Kezar Life Sciences, Inc. |
KZR |
Director |
2022-01-03 |
63,690 |
2018-06-25 |
0 |
Premium* |
|
|
Adicet Bio, Inc |
ACET |
Director |
2023-06-01 |
5,900 |
2023-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
156 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VSTM |
Verastem, Inc. |
Director |
– • – |
2015-08-24 |
4 |
S |
$6.46 |
$13,374 |
D/D |
(2,070) |
0 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2019-12-19 |
4 |
GD |
$0.00 |
$0 |
I/I |
34,626 |
0 |
0 |
- |
|
| VSTM |
Verastem, Inc. |
Director |
– • – |
2015-03-19 |
4 |
S |
$10.96 |
$10,192 |
D/D |
(930) |
2,070 |
0 |
- |
|
| VSTM |
Verastem, Inc. |
Director |
– • – |
2014-09-17 |
4 |
B |
$9.10 |
$27,300 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| VSTM |
Verastem, Inc. |
Director |
– • – |
2018-09-28 |
4 |
B |
$7.49 |
$29,960 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
| ACET |
Adicet Bio, Inc |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,900 |
5,900 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chief Medical Officer |
• – – |
2009-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
0 |
- |
|
| VSTM |
Verastem, Inc. |
Director |
– • – |
2018-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
8,000 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chief Medical Officer |
• – – |
2010-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
9,000 |
0 |
- |
|
| KZR |
Kezar Life Sciences, Inc. |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,516 |
63,690 |
0 |
- |
|
| KZR |
Kezar Life Sciences, Inc. |
Director |
– • – |
2022-01-03 |
4 |
AS |
$16.45 |
$82,250 |
D/D |
(5,000) |
63,690 |
0 |
% |
|
| KZR |
Kezar Life Sciences, Inc. |
Director |
– • – |
2022-01-03 |
4 |
OE |
$5.91 |
$29,550 |
D/D |
5,000 |
68,690 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2017-12-18 |
4 |
AS |
$9.16 |
$91,553 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-01-18 |
4 |
AS |
$10.09 |
$100,882 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-02-20 |
4 |
AS |
$14.79 |
$147,872 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-03-19 |
4 |
AS |
$15.29 |
$152,895 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-04-18 |
4 |
AS |
$14.79 |
$147,878 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-05-18 |
4 |
AS |
$19.39 |
$193,870 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-06-18 |
4 |
AS |
$18.66 |
$186,558 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-07-18 |
4 |
AS |
$18.27 |
$182,686 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-08-20 |
4 |
AS |
$17.46 |
$174,568 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-09-18 |
4 |
AS |
$18.26 |
$182,615 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-10-18 |
4 |
AS |
$12.63 |
$126,304 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-11-19 |
4 |
AS |
$11.14 |
$4,455 |
D/D |
(400) |
512,143 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-11-26 |
4 |
AS |
$11.00 |
$105,600 |
D/D |
(9,600) |
512,143 |
0 |
- |
|
156 Records found
|
|
Page 1 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
